News
OCGN
1.760
-5.88%
-0.110
Weekly Report: what happened at OCGN last week (0406-0410)?
Weekly Report · 2h ago
Ocugen Inc. Stock Falls 5.9%, Underperforms Market
Dow Jones · 2d ago
Ocugen (OCGN) Receives a Buy from Noble Financial
TipRanks · 6d ago
Weekly Report: what happened at OCGN last week (0330-0403)?
Weekly Report · 04/06 09:39
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
Reuters · 04/01 16:14
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Reuters · 04/01 13:14
Ocugen completes dosing in GARDian3 trial
TipRanks · 04/01 11:56
BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks
Reuters · 04/01 11:40
BUZZ-Ocugen rises after finishing patient dosing in late-stage eye gene therapy trial
Reuters · 04/01 11:16
Ocugen completes dosing in Phase 2/3 Stargardt gene therapy trial ahead of schedule
Reuters · 04/01 11:05
OCUGEN ANNOUNCES EARLY COMPLETION OF DOSING IN PHASE 2/3 PIVOTAL CONFIRMATORY TRIAL OF OCU410ST FOR STARGARDT DISEASE
Reuters · 04/01 11:02
Chardan sees positive read-through to Annexon’s vonaprument from Apellis deal
TipRanks · 03/31 17:10
Ocugen Inc. Stock Slips 6.4%, Underperforms Market
Dow Jones · 03/30 20:33
Weekly Report: what happened at OCGN last week (0323-0327)?
Weekly Report · 03/30 09:39
Ocugen Inc. Stock Sheds 4.6%, Underperforms Market
Dow Jones · 03/27 20:35
Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies
TipRanks · 03/27 12:23
Canaccord Genuity Sticks to Its Buy Rating for Ocugen (OCGN)
TipRanks · 03/26 11:16
Ocugen: Encouraging Phase 2 OCU410 Data in Geographic Atrophy Underpin Buy Rating and Long-Term Upside Potential
TipRanks · 03/25 19:15
Ocugen Price Target Maintained With a $7.00/Share by Chardan Capital
Dow Jones · 03/25 18:23
Ocugen Is Maintained at Buy by Chardan Capital
Dow Jones · 03/25 18:23
More
Webull provides a variety of real-time OCGN stock news. You can receive the latest news about Ocugen Inc through multiple platforms. This information may help you make smarter investment decisions.
About OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.